How Much Does GeneSight Cost? Full Breakdown Plus Alternatives

People ask about GeneSight's cost because the answer is genuinely confusing. The list price, the insured patient price, and the actual out-of-pocket cost you will pay are three different numbers. This guide walks through each one, explains why they differ, and shows how the cost compares to alternative pharmacogenetic tests (including Gene2Rx, which starts at $5 because it works with 23andMe or AncestryDNA data you may already have).

GeneSight's full list price has historically been around $2,000, though the exact number depends on the panel tier. This is what Myriad Genetics (GeneSight's parent company) bills insurance. Most patients never pay this number directly. It is what shows up on the explanation-of-benefits documents insurers send out, before any insurance adjustment or patient-responsibility calculation.

For patients with insurance that Myriad contracts with, the company caps out-of-pocket responsibility at around $330. Some patients pay less than that after insurance adjustments. For patients who qualify, Myriad's financial assistance program can reduce the cost further. Insurance coverage usually requires a qualifying psychiatric diagnosis and a prescribing provider's documentation of medical necessity. If any of those pieces is missing, insurance may not pay.

If you are uninsured, on a plan that does not cover pharmacogenetic testing, or your claim is denied for missing documentation, the cost moves closer to the list price. Patients in this situation often report out-of-pocket bills of several hundred to over a thousand dollars for GeneSight. This is the scenario most people mean when they say GeneSight was expensive.

The $330 patient maximum covers the test itself. It does not include the costs of getting to the test: the appointment with a prescribing provider where the test is ordered, follow-up appointments where results are discussed, any related labs or evaluations, or time off work. These ancillary costs vary with your insurance's copay and coinsurance structure, but they are real and worth factoring in when comparing to direct-to-consumer alternatives that do not require a prescriber visit.

The underlying science in any pharmacogenetic test is the same. Price differences between services come from the cost structure of delivering the test, not accuracy or gene coverage.

Whatever you spend on pharmacogenetic testing, the underlying genotype data is the same. A CYP2C19 poor metabolizer is a CYP2C19 poor metabolizer whether the test was run by Myriad, by Genomind, or by a service reading existing 23andMe data. The actionable clinical recommendation comes from CPIC guidelines,^[1] which every reputable test follows.

Cost is a reasonable reason to shop around for pharmacogenetic testing. Services like Gene2Rx that analyze your existing genetic data run $5 to $49 because they skip the clinical-lab infrastructure, insurance billing, sample-collection logistics, and physician outreach that push commercial PGx tests to their list prices. The underlying pharmacogenetic interpretation is comparable. One real trade-off: clinical tests like GeneSight use clinical-grade, validated assays and can detect structural variants like CYP2D6 gene duplications that consumer genotyping arrays miss. For most prescribing questions a $35 or $49 report is a strong starting point; for high-stakes decisions, a clinician may confirm a specific result with a clinical-grade test.

• Looking for a GeneSight Alternative? Here's the Short Answer
• GeneSight vs Genomind vs Gene2Rx: Three-Way Pharmacogenetic Test Comparison
• Can I Get GeneSight Without a Doctor? Direct-to-Consumer Alternatives
• Looking for a Genomind Alternative? Here's What to Know
• How to Read Your GeneSight Report: Green, Yellow, and Red Explained
• 23andMe Pharmacogenetics: How to Get a Drug Response Report From Your Existing Data

For many patients, yes, with a qualifying psychiatric diagnosis and documentation of medical necessity. Myriad bills insurance directly and is in network with many major plans. Coverage and patient responsibility vary by plan. Call your insurer to verify before ordering.

Direct-to-consumer services that analyze your existing 23andMe, AncestryDNA, or whole-genome data are much cheaper than clinical tests that require a new sample. Gene2Rx starts at $5 for a starter report, $35 for a psychiatric-focused report, or $49 for the full 110-medication report. Clinical pharmacogenetic tests like GeneSight and Genomind typically run from a couple hundred dollars with insurance to several hundred or more without.

The list price reflects the cost of running a full clinical-test infrastructure: FDA-compliant lab processing, insurance billing, sample-collection kits, sales reps who market to psychiatrists, clinical-trial funding, and support staff for providers. These are legitimate business costs, but they push the end-user price well above what the underlying lab work alone would suggest.

Yes, but the cost without insurance is much higher. Myriad offers a financial assistance program for patients who qualify based on income. If you are uninsured and cost-sensitive, compare the GeneSight price to direct-to-consumer pharmacogenetic services that do not require insurance paperwork.

No. The GeneSight price covers the test and its report. Discussing the results with your clinician happens through normal appointments, which have their own copays and coinsurance costs depending on your plan.